Delix Therapeutics
Prof David E. Olson, PhD studied chemistry and neuroscience at Stanford University and the Stanley Center for Psychiatric Research at the Broad Institute of MIT and Harvard. His academic lab at the University of California, Davis discovered that psychedelics promote structural and functional neuroplasticity in the cortex. They coined the term “psychoplastogen” to describe small molecules that produce rapid and long-lasting psychedelic- and ketamine-like effects on neuronal structure, and they invented the first non-hallucinogenic psychoplastogens capable of producing sustained therapeutic effects in preclinical models after a single dose.
This person is not in any offices
Delix Therapeutics
Delix Therapeutics is applying modern tools of pharmaceutical development to some of nature's most ancient therapies, psychedelics. Through its discovery platform, Delix has identified a new class of non-hallucinogenic versions of psychedelic compounds with favorable safety and therapeutic profiles. Delix is rapidly advancing these psychoplastogen compounds through preclinical and clinical development, with the goal of one day alleviating mental suffering through its FDA-approved, take-home medicines.